Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $494.72, for a total value of $1,978,880.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at $64,313.60. This trade represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $510.94 on Thursday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $513.93. The business has a fifty day moving average of $460.85 and a two-hundred day moving average of $378.34. The stock has a market cap of $22.00 billion, a PE ratio of 19.36, a PEG ratio of 4.96 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter last year, the company posted $6.39 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. Analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its position in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. boosted its stake in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $317,617,000. Assetmark Inc. raised its stake in shares of United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after buying an additional 197,384 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in United Therapeutics by 0.7% in the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock valued at $192,571,000 after buying an additional 4,145 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on UTHR shares. Cantor Fitzgerald boosted their target price on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Bank of America boosted their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Royal Bank Of Canada raised their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. Finally, Wells Fargo & Company increased their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.